PTC Therapeutics

hC Bioscience's Preclinical Study Shows Promise for tRNA-Based Cancer Therapy

Retrieved on: 
Wednesday, June 7, 2023
Cancer, PTC Therapeutics, Therapy, Mutation, Patient, Small RNA, Medical imaging, Telescopic sight

Boston, Massachusetts--(Newsfile Corp. - June 7, 2023) - hC Bioscience announced its tRNA-based therapy demonstrated proof-of-concept in an in vivo model of metastatic colorectal cancer with 75% tumor growth inhibition.

Key Points: 
  • Boston, Massachusetts--(Newsfile Corp. - June 7, 2023) - hC Bioscience announced its tRNA-based therapy demonstrated proof-of-concept in an in vivo model of metastatic colorectal cancer with 75% tumor growth inhibition.
  • Because nonsense mutations drive an estimated 10-15% of cancers, tRNA-based therapy represents a potential new modality for the treatment of cancer.
  • hC Bioscience's engineered tRNA demonstrated preclinical proof-of-concept in metastatic colorectal cancer, paving the way for treating cancer with tRNA-based therapy.
  • A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

Retrieved on: 
Thursday, June 8, 2023
Workforce, LLP, Employment, PTC Therapeutics, Friedreich's ataxia, PTC, Research, Patient, United, Pomerantz, Therapy, Private investigator

NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT).

Key Points: 
  • NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether PTC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

PTC Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses

Retrieved on: 
Tuesday, June 6, 2023
PTC, PTC Therapeutics, Therapy

LOS ANGELES, June 06, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT) investors that the law firm has initiated an investigation on behalf of investors that lost money on their PTC stock. PTC investors are encouraged to contact the firm to discuss their legal rights.

Key Points: 
  • LOS ANGELES, June 06, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT ) investors that the law firm has initiated an investigation on behalf of investors that lost money on their PTC stock.
  • PTC investors are encouraged to contact the firm to discuss their legal rights.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

PTC Therapeutics to Participate at Upcoming Investor Conferences

Retrieved on: 
Friday, June 2, 2023
PTC, PTC Therapeutics, Therapy, EDT, Cryptocurrency

SOUTH PLAINFIELD, N.J., June 2, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:

Key Points: 
  • SOUTH PLAINFIELD, N.J., June 2, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
    Wednesday, June 7 at 12:30 p.m. EDT
    Wednesday, June 14 at 1:40 p.m. EDT/10:40 a.m. PDT
    The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentations.
  • It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Retrieved on: 
Wednesday, May 24, 2023
Legal, Professional Services, Certification, Ethics, Suite, PTC Therapeutics, Therapy, Security (finance)

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or “the Company”) (NASDAQ: PTCT ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or “the Company”) (NASDAQ: PTCT ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Retrieved on: 
Wednesday, May 24, 2023
Class Action Lawsuit, Professional Services, Legal, Certification, Ethics, Suite, PTC Therapeutics, Therapy, Security (finance)

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or “the Company”) (NASDAQ: PTCT ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or “the Company”) (NASDAQ: PTCT ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial

Retrieved on: 
Tuesday, May 23, 2023
PTC Therapeutics, Friedreich's ataxia, PTC, Medulla oblongata, EDT, HIV disease progression rates, Patient, Disease, FA, Therapy, News, Conference, Safety, Medical imaging, Pharmaceutical industry

SOUTH PLAINFIELD, N.J., May 23, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported topline results from the MOVE-FA trial of vatiquinone in patients with Friedreich ataxia. The study did not meet its primary endpoint of statistically significant change in mFARS score at 72 weeks in the primary analysis population. However, vatiquinone treatment did demonstrate significant benefit on key disease subscales and secondary endpoints. In addition, in the population of subjects that completed the study protocol, significance was reached in the mFARS endpoint and several secondary endpoints.

Key Points: 
  • SOUTH PLAINFIELD, N.J., May 23, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported topline results from the MOVE-FA trial of vatiquinone in patients with Friedreich ataxia.
  • However, vatiquinone treatment did demonstrate significant benefit on key disease subscales and secondary endpoints.
  • The MOVE-FA trial enrolled 146 pediatric and adult patients, the majority of which were under 18 years of age.
  • Overall, vatiquinone was demonstrated to be well tolerated, adding to the large volume of safety data collected in other pediatric clinical studies.

PTC Therapeutics Announces Strategic Pipeline Prioritization

Retrieved on: 
Tuesday, May 23, 2023
Workforce, PTC Therapeutics, Friedreich's ataxia, PTC, Research, Brain, Angelman syndrome, EDT, CNS, DSM-IV codes, Patient, OPEX, Growth, Therapy, News, Conference, Pharmaceutical industry, Eladocagene exuparvovec

SOUTH PLAINFIELD, N.J., May 23, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the discontinuation of preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization. PTC will continue its development and global commercialization of Upstaza, the first-ever approved gene therapy directly administered to the brain. As a result of the prioritization, estimated reductions of approximately fifteen percent in residual 2023 operating expenses (OPEX) are expected. Additional 2023 OPEX guidance will be provided as part of second quarter earnings.

Key Points: 
  • SOUTH PLAINFIELD, N.J., May 23, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the discontinuation of preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization.
  • PTC will continue its development and global commercialization of Upstaza, the first-ever approved gene therapy directly administered to the brain.
  • As a result of the prioritization, estimated reductions of approximately fifteen percent in residual 2023 operating expenses (OPEX) are expected.
  • In addition, PTC Therapeutics also announced today that PTC's Chief Financial Officer Emily Hill has been relieved of her responsibilities and will be leaving the organization.

PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients

Retrieved on: 
Wednesday, May 17, 2023
PKU, PTC, PTC Therapeutics, Phenylketonuria, Therapy, Patient, Pharmaceutical industry, PHE

SOUTH PLAINFIELD, N.J., May 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the primary endpoint was achieved in the APHENITY, Phase 3 registration-directed clinical trial of sepiapterin in adult and pediatric patients with phenylketonuria (PKU).

Key Points: 
  • SOUTH PLAINFIELD, N.J., May 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the primary endpoint was achieved in the APHENITY, Phase 3 registration-directed clinical trial of sepiapterin in adult and pediatric patients with phenylketonuria (PKU).
  • "The positive results from the APHENITY trial bring us one step closer to providing a therapy that could deliver meaningful benefit to PKU patients," said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics.
  • The placebo-controlled portion of the study included 98 patients in the primary analysis population.
  • Minimal reductions in Phe levels were observed in the placebo treated patients resulting in a highly statistically significant sepiapterin treatment benefit (p

PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients

Retrieved on: 
Wednesday, May 17, 2023
PKU, PTC, PTC Therapeutics, Phenylketonuria, Therapy, Patient, Pharmaceutical industry, PHE

SOUTH PLAINFIELD, N.J., May 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the primary endpoint was achieved in the APHENITY, Phase 3 registration-directed clinical trial of sepiapterin in adult and pediatric patients with phenylketonuria (PKU).

Key Points: 
  • SOUTH PLAINFIELD, N.J., May 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the primary endpoint was achieved in the APHENITY, Phase 3 registration-directed clinical trial of sepiapterin in adult and pediatric patients with phenylketonuria (PKU).
  • "The positive results from the APHENITY trial bring us one step closer to providing a therapy that could deliver meaningful benefit to PKU patients," said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics.
  • The placebo-controlled portion of the study included 98 patients in the primary analysis population.
  • Minimal reductions in Phe levels were observed in the placebo treated patients resulting in a highly statistically significant sepiapterin treatment benefit (p